# Pharmacokinetics and Safety/Tolerability of YY-201 in Comparison to Dutasteride and Tadalafil

> **NCT03240939** · PHASE1 · COMPLETED · sponsor: **Yuyu Pharma, Inc.** · enrollment: 36 (actual)

## Conditions studied

- Benign Prostatic Hyperplasia

## Interventions

- **DRUG:** Dutasteride 0.5 mg
- **DRUG:** Tadalafil 5 mg
- **DRUG:** YY-201

## Key facts

- **NCT ID:** NCT03240939
- **Lead sponsor:** Yuyu Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-27
- **Primary completion:** 2017-07-07
- **Final completion:** 2017-10-10
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2017-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03240939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03240939, "Pharmacokinetics and Safety/Tolerability of YY-201 in Comparison to Dutasteride and Tadalafil". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03240939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*